Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality following heart attacks in patients who develop indications of congestive heart failure. In the paediatric population it is used most commonly for the treatment of heart failure, hypertension in type 1 diabetes and diabetic nephropathy. Due to the lack of a suitable liquid formulation, the current study evaluates the development of a range of oral liquid formulations of ramipril along with their in vitro and in vivo absorption studies. Three different formulation development approaches were studied: solubilisation using acetic acid as a co-solvent, complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) and suspension development using xanthan gum.
Introduction
Ramipril is used mainly in the treatment of mild to severe hypertension as well as to reduce the incidence of fatality following heart attacks in patients who develop indications of congestive heart failure. It may also be used to slow the progression of kidney disease in patients who suffer from high blood pressure in conditions such as diabetes, (1) (2) (3) microalbuminuria (albumin in the urine) or nephropathy. (2, 3) Once administered, maximum absorption is approximately 50-60%(4) through solute transporters in the small intestine. (5) In the paediatric population, ramipril is used most commonly for the treatment of heart failure, hypertension in children with type 1 diabetes and also in the treatment of diabetic nephropathy. (6) Solid oral dosage forms are the preferred method of administration for the general population. These however are often difficult or impossible for paediatric patients to swallow safely. (7) The preferred dosage forms for children include oral solutions, syrups, suspensions, and drops due to their wider acceptability and dose flexibility. Additionally, liquid forms of medication may also be administered by oral feeding tube when required. (8) Dose volume is a critical factor to consider during formulation development as the typical target dose volumes for paediatric liquid formulations are ≤5ml for children younger than 5 years and ≤10ml for children 5 years and older.
During formulation, the physiochemical properties of the drug governs the route of formulation with solubility, pKa, and palatability being primary concerns. Careful excipient selection is imperative when targeting paediatrics to achieve the desired formulation effect whilst still accommodating the highly sensitive nature of the patient segment. The European Medicines Agency (EMEA) acknowledges that there may be no single formulation which meets all requirements for all paediatric age groups but dosage forms containing minimal number and quantities of excipients which offer dose flexibility and cheaper cost of production are preferred (EMEA/CHMP/PEG/194810/2005). (9) Ramipril is commercially available as tablets, capsules and oral solution. However, the oral liquid is not prescribed for paediatric population owing to the reported toxicity implications associated with the use of high concentration of propylene glycol (E1520) within the formulation (EMEA/CHMP/PEG/194810/2005). (11) Research into the production of an age appropriate dosage form targeting paediatrics, was considered a priority as communicated in the revised priority list for studies into off-patent paediatric medicinal products (EMA/480197/2010). (10) The current study aims to develop oral liquid formulations of ramipril which offers target pharmaceutical product profile (TPPP) comprising of small dose volume (not more than 5 mL to deliver 5mg, which is the common dose in children), long term stability, reduced dosing frequency (related to dose volume), flexibility for dose manipulation and evidence of biopharmaceutical performance. Three different strategies which included two solution based and one suspension based formulation approaches that meet the TPPP were investigated.
Solubilisation of ramipril was studied using acetic acid as a co-solvent and through complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) whereas suspension was formulated using hydrophilic suspending agent.
Acetic acid was selected for use as a co-solvent in the solubilisation of ramipril as it dissolves the drug freely and is Generally Recognised as Safe (GRAS). Similarly, HP-β-CD (modified β-CD) was used for drug complexation as it offers improved solubility when compared to the parent molecule which would result in a linear relationship between the improvement in apparent solubility (drug) with increasing cyclodextrin concentration. Although parenteral administration of beta cyclodextrins may lead to nephrotoxicity, oral delivery is considered safe due to their low bioavailability (<1%). (12) The formulation of oral suspension of ramipril was studied using xanthan gum as the suspending agent due to its pseudoplastic properties and solubility in water. Additionally, xanthan gum is suitable for use in a wide range of pH (between 3-12) which has benefits over hydrophobic polymers such as ethylcellulose which are sensitive to acidic conditions (as ramipril is most stable in an acidic environment) and require heating and cooling cycles to achieve solubilisation.
Following formulation development, stability testing was carried out to ensure that the formulations achieved the long term stability requirement listed in the TPPP.
Biopharmaceutical performance of the dosage forms was evaluated and included the measurement of drug permeability using cell culture models followed by in vivo assessment in rats to determine the pharmacokinetic profile. Previous work has reported a correlation of 
Methods

HPLC method for the detection of ramipril
A Dionex GP50 Gradient Pump coupled to a Dionex UVD170U detector and a Dionex A550 auto sampler was used for HPLC studies. Perchlorate Buffer and Acetonitrile (55:45) was used as the mobile phase and the stationary phase was a C18 reverse phase column (150 x 4.5mm with 5µm Particle Size) with a flow rate of 1mL/min at a detection wavelength of 216nm. The injection volume was 50µl and the run time was 10 minutes (min). Calibration standards were produced via serial dilution in methanol and acetonitrile (Diluent A) (50:50).
The standards were then diluted 1:5 in diluent B (water and acetonitrile, 45:55). The method was validated following the guidelines from International Conference on Harmonisation (ICH) (ICH Topic Q 2 (R1) 1995).(15)
Method for particle size analysis
Particle size for suspensions was measured using Sympatec Helos (UK) particle sizer.
For the measurements of size, 100 μL of a sample was pipetted into a glass quartz cuvette (a signal of at least 15% scattering was required for an adequate reading). Three measurements were taken for each formulation and an average result obtained for size and polydispersity.
Method for zeta potential analysis
Zeta potential was analysed using a Brookhaven zeta potential analyser in conjunction with a BI-ZEL electrode assembly (Brookhaven Instruments). A 1:10 dilution was made of each formulation in distilled water to bring detection levels into a readable range and placed into the zetasizer cuvette. Triplicate readings were taken from three batches for each formulation and the mean value reported.
Co-solvent approach to the solubilisation of ramipril
Acetic acid solutions were produced at concentrations of 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.04%, 0.03%, 0.02% and 0.01% v/v. Ramipril was then added to each co solvent at 0.01%w/v. The solutions were stirred for 1 hour (h) and filtered before HPLC to confirm complete solubilisation.
Cyclodextrin Approach to the Solubilisation of Ramipril
Phase solubility
Method described by Higuchi and Connors was used to investigate phase solubility of ramipril and HP-β-CD complex. (16) This method was also adapted to assay the effect of temperature and pH on solubilisation. Six concentrations of cyclodextrin were produced in distilled water ranging between 1.2mM to 3.75µM using serial dilution. These were cooled to 15°C and excess ramipril was added. Solutions were then maintained at this temperature for 1h at which point a sample was taken, filtered and prepared for HPLC. This was repeated at 30°C, 45°C, 60°C and 75°C. Similarly for pH, six concentrations of cyclodextrin were produced from 1.2mM down to 3.75µM using serial dilution. These were produced at pH 3, 5 and 7 to which excess ramipril was added. Solutions were left stirring for 1h before samples were filtered and prepared for HPLC analysis.
Determination of ramipril -HP-β-CD binding constant and stoichiometry
In order to identify the binding constant and stoichiometry for drug-cyclodextrin complex, known amounts of ramipril were added to 4.8x10 
Investigation into the rate and volume of sedimentation
The theoretical rate and volume of sedimentation was calculated using Stokes equation. For investigation into the actual rate and volume of sedimentation, ramipril suspensions containing 0.1-0.5%w/v Xantural® were prepared and allowed to stand undisturbed for four weeks at 20°C. Actual sedimentation was obtained from the sedimentation volume. Studies were carried out on three different batches of the formulations.
Particle size and investigation into Ostwald Ripening
Ramipril suspensions were produced in distilled water using Xantural® 180 at concentrations ranging between 0.1-0.5% w/v and particle size was measured using a Sympatec HELIOS/BF particle size analyser. The suspensions were heated and cooled repeatedly and particle size was measured after each cycle. Microscopic images were also recorded to document any crystal growth. Each cycle involved heating to 40°C for 24h
followed by cooling to 4°C for 24h . Studies were carried out on three different batches of the formulations.
Analysis of zeta potential
Ramipril suspensions (0.1-0.5%w/v Xantural® 180) were analysed using a zeta plus zeta potential analyser in conjunction with a BI-ZEL electrode assembly (Brookhaven Instruments). 100µl of the formulation was added to the cuvette containing approximately 1.5ml of distilled water and zeta potential was recorded on three different batches of the same formulation. The values presented are the mean of the three measurements.
Stability analysis
The conditions for stability testing were based on the guidelines set out in the ICH Harmonisation Guidelines Q1A(R2). (17) Stability investigations were carried out at 40°C and 75% humidity for accelerated testing and 25°C and 60% humidity for long term stability testing.
The final formulations were tested on a monthly basis and assessed quantitatively by HPLC and for pH. Formulations were also assessed qualitatively for colour changes and odour and suspensions were assessed for resuspendibility of any sediment.
Assessment of absorption In Vitro
Culture of Caco-2 cells for permeability assay
Caco-2 cells (passage 45) (A kind gift from Dr Andrew Collett and Dr Daniel Patten at the University of Huddersfield) were seeded at a density of 1.3x10 5 cells/cm 2 onto permeability supports (Appelton Woods Ltd). Cells were cultured in an incubator (Sanyo) at 37°C in a humidified 5% CO2/95% air atmosphere. Media was changed every 2-3 days over a three week period. Trans-epithelial electronic resistance (TEER) measurements were taken following each media change and immediately before and after experiments using an EVOM -Epithelial Voltohmmeter (World Precision Instruments Ltd). Minimum TEER threshold of 350Ωcm 2 (before and after the experiment) was set as a standard to ensure monolayer integrity.
Trans-epithelial flux of ramipril across Caco-2 monolayers
Culture media was removed and the monolayers were washed and incubated (pH range 6.7 -7.8) at 37°C for 30min with 2.5ml and 1.5ml of HBSS basolaterally and apically respectively. In each case, HBSS was then replaced in the apical compartment with 1.5ml of the optimised formulation to be tested. Monolayer containing transwells (not exposed to the drug) were used as controls. experiments on ramipril solutions developed using co-solvency and cyclodextrin approaches in addition to the suspension formulation. These assays were carried out following the directions for Agilent Technologies' one-colour microarray-based gene expression analysis low input quick amp labelling kit. In short, 1.5µl of 50ng total RNA was mixed with 2µl of spike mix (dilution 4), cDNA master mix (Agilent Technologies, Santa Clara, CA) was used to prepare cDNA for all samples ahead of labelling with cyanine 3-CTP (Cy3) in the labelling reaction. The labelled and amplified cRNA was then purified using RNeasy mini spin columns (Qiagen) and quantified using Nanodrop ND-1000 UV-VIS spectrophotometer (Thermoscientific, Wilmington, DE). All samples were then hybridised to Agilent 4x44K whole genome arrays for 17(h) at 65°C in a hybridisation oven (Sheldon manufacturer, Corneilus, OR). Following the hybridisation stage slides were washed using the gene expression wash buffer kit (Agilent Technologies, Santa Clara, CA) and acetonitrile. Scanning was carried out at using Agilent Scanner (Agilent Technologies, Santa Clara, CA) at a resolution of 50n.
Feature Extraction software (V10.7, Santa Clara, CA) was implemented to examine the quality of the 16-bit TIFF images obtained by microarray scanning. 
Assessment of absorption in vivo.
Experimentation strictly adhered to the 1986 Scientific Procedures Act (UK) and was carried out in a designated establishment. Wistar rats with a body weight of approximately 250g-300g were used. Prepared formulations were loaded into a 1ml syringe and administered via oral gavage. Dosing was calculated depending upon the weight of each individual animal (5mg/kg) and formulations were diluted in water. Following dosing, an additional 1ml of H2O was administered to rinse in the formulations. Blood samples (45µl) were taken via tail bleeds at 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h and 4h time points following administration.
Plasma was extracted from blood samples by centrifugation at 2800 x g for 10min. The plasma samples were then diluted 1:5 in mobile phase and analysed using HPLC.
Results and Discussion
The first phase of product development was focused on excipient selection and process optimisation. One of the main considerations was to ensure that the formulations were developed with minimal number of excipients at their lowest possible concentration. The first approach towards the development of oral liquid solution was studied using acetic acid as a co-solvent to enhance the apparent solubility of ramipril. The final formulation composition and process consisted of addition of 1mg/ml of ramipril into 0.02% v/v acetic acid -water cosolvent mixture under stirring to ensure complete solubilisation and homogeneity. This was followed by the addition of other excipients in the following order: ascorbic (0.1mg/ml; antioxidant), xylitol (200mg/ml; sweetener), parabens (propyl -0.1mg/ml, butyl -0.06mg/ml; preservative) and finally orange flavour (0.1%v/v) ( Table 1) .
Co
Cyclodextrin approach to solubilising ramipril
Cyclodextrin based liquid dosage forms were investigated as they provide dual advantage including enhancement of apparent drug solubility as well as taste masking through drug encapsulation.
Phase Solubility
Phase solubility profile of ramipril in the presence of various concentrations HP-β-CD was studied to identify the stoichiometry during drug-complex formation. The results showed that the phase solubility profile for ramipril complexed with HP-β-CD was that of the AL type molecules. In the current study, as the target dose of ramipril in the formulation is 1mg/ml (which equates to 0.24mM), it can be estimated that 0.24mM of cyclodextrin will be required to solubilise the drug (0.24mM equates to 3.5mg/ml).
Drug solubility following complexation with cyclodextrin has been show to vary upon modification of the pH of a system. This possibly occurs as a result of alteration to the complexation constant with solubility increases resulting in an increase in complexation constant. (20) As shown in Figure 2 , the optimum pH for the solubilisation of ramipril using HP-β-CD was 3 with both pH 5 and 7 showing reduced solubilisation. These differences in solubilisation at different pH values could possibly be due to the existence of either ionised or un ionised form of the drug. The concentration of ionised form of ramipril is higher at pH close to neutral and previous research has shown that the degree of complex formation for HP-β-CD is lowered for ionised molecules when compared with their uncharged form. (21) The negative charge present following ionisation of ramipril could result in repulsive forces between cyclodextrin and drug molecules and between drug molecules leading to a reduction in complexation.
Following the evaluation of drug-cyclodextrin molar ratio and the impact of pH on the resultant complex, the production of the formulation consisted of the preparation of cyclodextrin solution by dissolving 3.51mg/mL of HP-β-CD in distilled water. The next stage included the addition of 1mg/ml ramipril under stirring until it was completely dissolved. Following this, the other excipients were added in the following order: ascorbic (0.1mg/ml; antioxidant), xylitol (200mg/ml; sweetener), parabens (propyl -0.1mg/ml, butyl -0.06mg/ml; preservative) and finally orange flavour (0.1%v/v) ( Table 1 ). The pH of the final formulation was pH 3.75.
Suspension formulation development
The development of a suspension requires selection and optimisation of a suitable concentration of suspending agent along with the assessment of sedimentation rate and resuspendibility of the formulation.
Suspension Rheology, rate and volume of sedimentation
The first sets of investigations included determination of flow properties of the suspending medium using shear rate response to changes in shear stress which was evaluated using a viscometer. Five different suspensions were produced using different showed that there was no increase in particle size when subjected to temperature changes between 4 and 40 O C.
The final composition and process for preparing ramipril suspensions included production of 0.1%w/v Xantural® 180 solution, into which 1mg/ml ramipril was then added slowly with vigorous stirring to ensure it is evenly distributed throughout the vehicle. This stage was followed by the addition of sodium meta bisulphate (10mg/ml; antioxidant), xylitol (400mg/ml; sweetener), sodium benzoate (5mg/ml; preservative) and strawberry flavour (0.2%v/v). The pH of the final formulation was 4.25.
For all the optimised dosage forms, it was inevitable to include lowest possible concentration of preservatives as the primary vehicle is water and supports microbial growth.
Taste assessment studies including indirect methods to evaluate taste such as drug release and dissolution testing (which are generally used for taste masked drug and require validation through direct taste assessment studies) have not been included as there are no taste related issues reported for ramipril. Indeed the inclusion of sweeteners and flavours in all the different dosage forms as well the formulation of drug complexed cyclodextrin liquid will ensure patient acceptability and compliance without any concerns for palatability. Following formulation profiling together with investigation of optimal process and excipient parameters that meet the TPPP, the next stage of evaluation consisted of stability testing and subsequent drug absorption and genomic analysis.
Stability Analysis
Over the course of six month for stability testing at accelerated conditions at 40°C and 75% relative humidity, the drug content of the formulations fell below 95% of the starting dose indicating that the formulations failed to display adequate stability in accordance with ICH guidelines. pH remained constant for the duration of the stability testing in accelerated conditions. At long term conditions at 25°C and 60% relative humidity, drug content for all of the formulations remained >95% of the starting dose and pH remained constant for the duration of the 12 month testing period. Additionally, all formulations maintained their aesthetics. Suspension formulations did not display any sedimentation throughout the study suggesting that the inherent limitations of physical instability experienced by many suspension based formulations was successfully overcome and that sedimentation was totally prevented.
Degradation seen under accelerated conditions is possibly as a result of the elevated temperature. Ramipril diketopiperazine (DKP) degradate is the primary degradation compound for ramipril. Degradation occurs through intramolecular condensation with the formation of a second amide bond. (22) The pH of the formulation in both accelerated and long term conditions did not change beyond the acceptance levels for the formulation. Additionally, the appearance and odour of the formulations remained acceptable for the duration of the stability testing in both long term and accelerated conditions. The results show that formulations do not require refrigeration but would require storage in a cool location (<25°C). 
In Vitro and In Vivo
Assessment of Absorption In Vivo
The plasma concentration-time profile for the formulations for in vivo absorption is shown in Figure 5 . From the plasma concentration-time profile, values for area under the curve (AUC), CMAX and TMAX were determined and are shown in Table 2 . Ramipril AUC values were within the anticipated range as its bioavailability is known to be highly variable between individuals with reports showing variation ranging between 6-60%. (4) Ramipril showed a CMAX of 10.48 µg/mL for the solution produced using co-solvent, 13.04µg/ml for the ramipril suspension and 29.58µg/mL for the ramipril solution produced using cyclodextrin as a solubiliser.
The findings for CMAX and TMAX reveal interesting findings; ramipril solution produced using co-solvent and the ramipril suspension showed TMAX at 2.5h after administration.
However, ramipril solution produced using cyclodextrin showed a much earlier TMAX occurring only 0.75h following administration. As the only formulation component which is unique to the ramipril solution produced using cyclodextrins as a solubiliser is the HP-β-CD it is possible that this excipient is responsible for the earlier TMAX and higher CMAX. There is evidence that HP-β-CD decreases GI transit time in rats thus shortening the time taken for the drug to reach the site of absorption. provide the platform to formulate better medicines for children using simple, cost effective and scalable processing parameters. 
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